Assessment of the methods used to detect HER2-positive advanced extramammary Paget’s disease

Ikuko Hirai, Keiji Tanese, Yoshio Nakamura, Atsushi Otsuka, Yasuhiro Fujisawa, Yuki Yamamoto, Hiroo Hata, Taku Fujimura, Shigeto Matsushita, Koji Yoshino, Kaori Kameyama, Masayuki Amagai, Takeru Funakoshi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The human epidermal growth factor receptor 2 (HER2) is recognized as an oncogene as well as a therapeutic target in various cancers. Certain patients with advanced extramammary Paget’s disease (EMPD) have also been reported to express HER2, which is therefore considered a therapeutic target for EMPD. However, an accurate methodology to determine HER2-positive EMPD has not been established. To assess the optimal methods for detection of HER2-positive EMPD, 73 EMPD samples were analyzed by immunohistochemical (IHC) staining, fluorescence in situ hybridization (FISH), and the HER2 testing algorithm for breast cancer of the American Society of Clinical Oncology/College of American Pathologists, which combined the results of IHC staining and FISH. The results showed discordance in the rate of positive IHC staining and FISH results. While 68.6% (24/35) of the metastatic samples showed equivocal or positive IHC staining, only 37.1% (13/35) were positive by FISH. To assess the accuracy of these methods, the degree of HER2 expression detected by each method was correlated with the staining profiles of activated downstream signaling pathways involving phosphorylated p44/42 MAPK (Thr202/Tyr204) (p-ERK1/2) and phosphorylated AKT (Ser473) (p-AKT). Among 16 lymph node metastasis samples, all HER2-positive samples as determined by the testing algorithm stained positively for both p-ERK1/2 and p-AKT. On the other hand, 10-14.3% of the samples determined by FISH or IHC showed negative staining for p-ERK1/2 and p-AKT. The results showed that combining the results of IHC and FISH according to the HER2 testing algorithm is a useful method for accurately evaluating HER2-positive EMPD.

Original languageEnglish
Article number92
JournalMedical Oncology
Volume35
Issue number6
DOIs
Publication statusPublished - 2018 Jun 1

Fingerprint

Extramammary Paget's Disease
Fluorescence In Situ Hybridization
Staining and Labeling
human ERBB2 protein
Negative Staining
Mitogen-Activated Protein Kinase 3
Oncogenes
Lymph Nodes
Breast Neoplasms
Neoplasm Metastasis

Keywords

  • AKT signaling pathway
  • Extramammary Paget’s disease
  • HER2
  • MAPK signaling pathway

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Assessment of the methods used to detect HER2-positive advanced extramammary Paget’s disease. / Hirai, Ikuko; Tanese, Keiji; Nakamura, Yoshio; Otsuka, Atsushi; Fujisawa, Yasuhiro; Yamamoto, Yuki; Hata, Hiroo; Fujimura, Taku; Matsushita, Shigeto; Yoshino, Koji; Kameyama, Kaori; Amagai, Masayuki; Funakoshi, Takeru.

In: Medical Oncology, Vol. 35, No. 6, 92, 01.06.2018.

Research output: Contribution to journalArticle

Hirai, I, Tanese, K, Nakamura, Y, Otsuka, A, Fujisawa, Y, Yamamoto, Y, Hata, H, Fujimura, T, Matsushita, S, Yoshino, K, Kameyama, K, Amagai, M & Funakoshi, T 2018, 'Assessment of the methods used to detect HER2-positive advanced extramammary Paget’s disease', Medical Oncology, vol. 35, no. 6, 92. https://doi.org/10.1007/s12032-018-1154-z
Hirai, Ikuko ; Tanese, Keiji ; Nakamura, Yoshio ; Otsuka, Atsushi ; Fujisawa, Yasuhiro ; Yamamoto, Yuki ; Hata, Hiroo ; Fujimura, Taku ; Matsushita, Shigeto ; Yoshino, Koji ; Kameyama, Kaori ; Amagai, Masayuki ; Funakoshi, Takeru. / Assessment of the methods used to detect HER2-positive advanced extramammary Paget’s disease. In: Medical Oncology. 2018 ; Vol. 35, No. 6.
@article{281e077f53154d9aae52eaced9024a8d,
title = "Assessment of the methods used to detect HER2-positive advanced extramammary Paget’s disease",
abstract = "The human epidermal growth factor receptor 2 (HER2) is recognized as an oncogene as well as a therapeutic target in various cancers. Certain patients with advanced extramammary Paget’s disease (EMPD) have also been reported to express HER2, which is therefore considered a therapeutic target for EMPD. However, an accurate methodology to determine HER2-positive EMPD has not been established. To assess the optimal methods for detection of HER2-positive EMPD, 73 EMPD samples were analyzed by immunohistochemical (IHC) staining, fluorescence in situ hybridization (FISH), and the HER2 testing algorithm for breast cancer of the American Society of Clinical Oncology/College of American Pathologists, which combined the results of IHC staining and FISH. The results showed discordance in the rate of positive IHC staining and FISH results. While 68.6{\%} (24/35) of the metastatic samples showed equivocal or positive IHC staining, only 37.1{\%} (13/35) were positive by FISH. To assess the accuracy of these methods, the degree of HER2 expression detected by each method was correlated with the staining profiles of activated downstream signaling pathways involving phosphorylated p44/42 MAPK (Thr202/Tyr204) (p-ERK1/2) and phosphorylated AKT (Ser473) (p-AKT). Among 16 lymph node metastasis samples, all HER2-positive samples as determined by the testing algorithm stained positively for both p-ERK1/2 and p-AKT. On the other hand, 10-14.3{\%} of the samples determined by FISH or IHC showed negative staining for p-ERK1/2 and p-AKT. The results showed that combining the results of IHC and FISH according to the HER2 testing algorithm is a useful method for accurately evaluating HER2-positive EMPD.",
keywords = "AKT signaling pathway, Extramammary Paget’s disease, HER2, MAPK signaling pathway",
author = "Ikuko Hirai and Keiji Tanese and Yoshio Nakamura and Atsushi Otsuka and Yasuhiro Fujisawa and Yuki Yamamoto and Hiroo Hata and Taku Fujimura and Shigeto Matsushita and Koji Yoshino and Kaori Kameyama and Masayuki Amagai and Takeru Funakoshi",
year = "2018",
month = "6",
day = "1",
doi = "10.1007/s12032-018-1154-z",
language = "English",
volume = "35",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "6",

}

TY - JOUR

T1 - Assessment of the methods used to detect HER2-positive advanced extramammary Paget’s disease

AU - Hirai, Ikuko

AU - Tanese, Keiji

AU - Nakamura, Yoshio

AU - Otsuka, Atsushi

AU - Fujisawa, Yasuhiro

AU - Yamamoto, Yuki

AU - Hata, Hiroo

AU - Fujimura, Taku

AU - Matsushita, Shigeto

AU - Yoshino, Koji

AU - Kameyama, Kaori

AU - Amagai, Masayuki

AU - Funakoshi, Takeru

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The human epidermal growth factor receptor 2 (HER2) is recognized as an oncogene as well as a therapeutic target in various cancers. Certain patients with advanced extramammary Paget’s disease (EMPD) have also been reported to express HER2, which is therefore considered a therapeutic target for EMPD. However, an accurate methodology to determine HER2-positive EMPD has not been established. To assess the optimal methods for detection of HER2-positive EMPD, 73 EMPD samples were analyzed by immunohistochemical (IHC) staining, fluorescence in situ hybridization (FISH), and the HER2 testing algorithm for breast cancer of the American Society of Clinical Oncology/College of American Pathologists, which combined the results of IHC staining and FISH. The results showed discordance in the rate of positive IHC staining and FISH results. While 68.6% (24/35) of the metastatic samples showed equivocal or positive IHC staining, only 37.1% (13/35) were positive by FISH. To assess the accuracy of these methods, the degree of HER2 expression detected by each method was correlated with the staining profiles of activated downstream signaling pathways involving phosphorylated p44/42 MAPK (Thr202/Tyr204) (p-ERK1/2) and phosphorylated AKT (Ser473) (p-AKT). Among 16 lymph node metastasis samples, all HER2-positive samples as determined by the testing algorithm stained positively for both p-ERK1/2 and p-AKT. On the other hand, 10-14.3% of the samples determined by FISH or IHC showed negative staining for p-ERK1/2 and p-AKT. The results showed that combining the results of IHC and FISH according to the HER2 testing algorithm is a useful method for accurately evaluating HER2-positive EMPD.

AB - The human epidermal growth factor receptor 2 (HER2) is recognized as an oncogene as well as a therapeutic target in various cancers. Certain patients with advanced extramammary Paget’s disease (EMPD) have also been reported to express HER2, which is therefore considered a therapeutic target for EMPD. However, an accurate methodology to determine HER2-positive EMPD has not been established. To assess the optimal methods for detection of HER2-positive EMPD, 73 EMPD samples were analyzed by immunohistochemical (IHC) staining, fluorescence in situ hybridization (FISH), and the HER2 testing algorithm for breast cancer of the American Society of Clinical Oncology/College of American Pathologists, which combined the results of IHC staining and FISH. The results showed discordance in the rate of positive IHC staining and FISH results. While 68.6% (24/35) of the metastatic samples showed equivocal or positive IHC staining, only 37.1% (13/35) were positive by FISH. To assess the accuracy of these methods, the degree of HER2 expression detected by each method was correlated with the staining profiles of activated downstream signaling pathways involving phosphorylated p44/42 MAPK (Thr202/Tyr204) (p-ERK1/2) and phosphorylated AKT (Ser473) (p-AKT). Among 16 lymph node metastasis samples, all HER2-positive samples as determined by the testing algorithm stained positively for both p-ERK1/2 and p-AKT. On the other hand, 10-14.3% of the samples determined by FISH or IHC showed negative staining for p-ERK1/2 and p-AKT. The results showed that combining the results of IHC and FISH according to the HER2 testing algorithm is a useful method for accurately evaluating HER2-positive EMPD.

KW - AKT signaling pathway

KW - Extramammary Paget’s disease

KW - HER2

KW - MAPK signaling pathway

UR - http://www.scopus.com/inward/record.url?scp=85046642784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046642784&partnerID=8YFLogxK

U2 - 10.1007/s12032-018-1154-z

DO - 10.1007/s12032-018-1154-z

M3 - Article

C2 - 29744813

AN - SCOPUS:85046642784

VL - 35

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 6

M1 - 92

ER -